TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) S.A.E.

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

RMDA

EGS381B1C015

Pharmaceuticals

End-of-day quote Egyptian Exchange Other stock markets 06:00:00 2024-04-27 pm EDT			5-day change	1st Jan Change
2.14 ^EGP	-3.60%		-15.75%	+29.70%

Mar. 19	Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E.(CASE:RMDA) dropped from EGX 30 Index

August 02, 2023 at 12:00 am EDT

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. has been dropped from EGX 30 Index.

Latest news about Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-15	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E.(CASE:RMDA) dropped from EGX 30 Index	23-08-02	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-14	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Ekuity B.V. acquired additional 5.38% stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. for approximately EGP 160 million.	22-09-14	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. announces an Equity Buyback for 10% of its issued share capital.	22-09-05	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. authorizes a buyback plan.	22-09-04	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
The Saudi Seventh Investment Company agreed to acquire additional 6.5% stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. for GGP 135 million.	22-04-25	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-24	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-16	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents Rameda S.A.E. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-09	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E.(CASE:RMDA) added to EGX 30 Index	21-08-02	CI
Equinox Pharma Holding Ltd. acquired additional 2.71% minority stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. for EGP 58.3 million.	21-07-28	CI
STenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. Announce Audited Consolidated Earnings Results for the Quarter Ended March 31, 2021	21-05-06	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents Rameda S.A.E. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-02	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents Rameda S.A.E. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-10	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents Rameda S.A.E. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-16	CI
Certain Ordinary Shares of Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. are subject to a Lock-Up Agreement Ending on 8-JUN-2020.	20-06-07	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. has completed an IPO in the amount of EGP 1.754984 billion.	19-12-08	CI
Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda Announces Standalone Earnings Results for the Nine Months Ended September 30, 2019	19-12-04	CI
Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda Announces Consolidated Earnings Results for the Nine Months Ended September 30, 2019	19-12-04	CI
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. has filed an IPO in the amount of EGP 1.754984 billion.	19-11-27	CI

Chart Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

Duration

Period

Chart Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

More charts

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E (RAMEDA) specializes in the manufacture and marketing of generic pharmaceutical products. The products include antibiotics, vitamins, analgesics, medicines for ophthalmological care, gastrointestinal, dermatological and cardiovascular diseases, food supplements, medical devices and veterinary products.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.14 EGP

Average target price

3.472 EGP

Spread / Average Target

+62.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) S.A.E.	+29.70%	69.08M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

Equities

RMDA

EGS381B1C015

Pharmaceuticals

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E.(CASE:RMDA) dropped from EGX 30 Index

Latest news about Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

Chart Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

Company Profile

Income Statement Evolution

Ratings for Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals